Nephros (NASDAQ:NEPH) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Nephros (NASDAQ:NEPH) to a hold rating in a report published on Monday morning,Zacks.com reports.

A number of other equities analysts have also commented on NEPH. Weiss Ratings lowered shares of Nephros from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday. Northland Securities started coverage on Nephros in a research report on Friday, July 17th. They set a “market perform” rating and a $4.00 target price for the company. One analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Nephros presently has an average rating of “Hold” and an average price target of $5.00.

Nephros Price Performance

Nephros stock opened at $3.59 on Monday. The business has a 50 day moving average of $3.47 and a 200-day moving average of $3.63. Nephros has a 1 year low of $2.66 and a 1 year high of $6.42. The company has a market capitalization of $38.98 million, a P/E ratio of 51.29 and a beta of 1.49.

Nephros (NASDAQ:NEPH) last posted its earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter, hitting the consensus estimate of $0.01. Nephros had a net margin of 4.06% and a return on equity of 7.66%. The business had revenue of $5.21 million for the quarter, compared to the consensus estimate of $5.02 million. Equities analysts anticipate that Nephros will post 0.03 EPS for the current year.

Hedge Funds Weigh In On Nephros

A number of hedge funds have recently bought and sold shares of the company. XTX Topco Ltd boosted its position in Nephros by 48.5% during the fourth quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock valued at $105,000 after acquiring an additional 7,062 shares during the last quarter. Marshall Wace LLP acquired a new stake in Nephros during the 4th quarter worth about $107,000. Renaissance Technologies LLC raised its position in shares of Nephros by 25.8% in the 4th quarter. Renaissance Technologies LLC now owns 103,772 shares of the company’s stock worth $506,000 after acquiring an additional 21,272 shares in the last quarter. Topline Capital Management LLC lifted its stake in shares of Nephros by 13.1% in the 2nd quarter. Topline Capital Management LLC now owns 477,449 shares of the company’s stock valued at $1,953,000 after purchasing an additional 55,360 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Nephros by 3.2% in the 2nd quarter. Geode Capital Management LLC now owns 93,187 shares of the company’s stock valued at $381,000 after purchasing an additional 2,898 shares during the period. Institutional investors own 41.10% of the company’s stock.

Key Nephros News

Here are the key news stories impacting Nephros this week:

• Neutral Sentiment: Northland Securities reiterated a “Market Perform” rating on Nephros and set a $4.00 price target, which is only modestly above the recent trading range and suggests limited near-term upside. Nephros analyst estimates and rating update
• Neutral Sentiment: The firm’s updated earnings estimates point to gradual improvement, with Northland forecasting roughly $0.03 EPS for FY2026 and $0.19 EPS for FY2027, plus quarterly EPS in the low cents range through 2027. That outlook is constructive, but not strong enough to trigger a clear bullish re-rating on its own. Nephros earnings estimates update
• Neutral Sentiment: Nephros also announced it will participate in Maxim Group’s “Health, Wellness & Longevity” Virtual Conference on July 22. Conference participation can increase visibility, but it does not by itself change fundamentals. Nephros conference announcement

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.